Skip to main navigation

Skip to main content

Investor Relations

Home

Press Releases

Investor Relations

Home

Press Releases

Year

November 23, 2020

Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference

November 11, 2020

Passage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene Therapy

November 11, 2020

Passage Bio to Participate in Upcoming November Investor Conferences

November 10, 2020

Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights

November 9, 2020

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

November 4, 2020

Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020

October 28, 2020

Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease

October 26, 2020

Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis

October 13, 2020

Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic

October 6, 2020

Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30

Investor Tools

Email Alerts
RSS Feeds
FAQs
Investor Contact

Contact

General inquiries: info@passagebio.com

Investors Contact: passagebio@sternir.com

Two Commerce Square
2001 Market Street, 28th Floor
Philadelphia, PA
19103

Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
End of the Day SEC Filing
Event
News
Weekly Summary

Email

Leave this field blank

© Passage BIO, Inc.. All Rights Reserved

Footer Links - Policy

Privacy Policy